On Thursday, Shares of Lions Gate Entertainment Corp. (USA) (NYSE:LGF), lost - 0.22% to $ 36.42.
In a move reflecting the continued growth of the Lionsgate (LGF) Motion Picture Group, producer Bobby Cohen (Now You See Me franchise, Revolutionary Road, Memoirs of a Geisha, Cider House Rules) and Lionsgate production executive Gillian Bohrer have been named Co-Presidents of Production for the Lionsgate label.
Veteran Lionsgate film executive Mike Paseornek has been named to the newly-created role of President of Production for the entire Lionsgate Motion Picture Group, overseeing production of films encompassed by the Company’s expanding array of labels. Geoff Shaevitz remains President of Production for Summit Entertainment, and Director of Development James Myers has been promoted to Vice President of Production for the Summit label under Mr. Shaevitz. Messrs. Cohen, Shaevitz and Paseornek and Ms. Bohrer all report directly to Lionsgate Motion Picture Group Co-President Erik Feig.
Lions Gate Entertainment Corp. engages in motion picture production and distribution, television programming and syndication, home entertainment, family entertainment, digital distribution, channel platforms, and international distribution and sales activities. The company operates through two segments, Motion Pictures and Television Production.
Shares of Idera Pharmaceuticals Inc (NASDAQ:IDRA), inclined 4.66% to $ 3.59, during its last trading session.
Idera Pharmaceuticals, declared that the company has reached a planned clinical research alliance with The University of Texas MD Anderson Cancer Center to advance clinical development of intratumoral TLR9 agonist in combination with checkpoint inhibitors. IMO-2125 is a TLR9 agonist which has been evaluated subcutaneously in over 80 human subjects, was well tolerated, and was shown to induce immune responses.
The company intends to initiate the first trial of the research alliance, a Phase 1/2 study to assess the safety and efficacy of Intratumoral IMO-2125 in combination with ipilimumab in patients with metastatic melanoma. In this trial, escalating doses of IMO-2125 will be administered intratumorally into a lesion, with a standard dosing regimen of ipilimumab. The primary objectives of the trial will be to determine the maximum tolerated dose (MTD) and characterize the dose-limiting toxicities (DLTs) of IMO-2125 when administered intratumorally in combination with ipilimumab, in addition to to determine the efficacy of the combination utilizing the immune-related response criteria (irRC). The company has already filed and received FDA feedback to a Pre-Investigational New Drug Application (PIND) for IMO-2125 and intends to submit an Investigational New Drug application (IND) and initiate the clinical study in the second half of this year. The trial will enroll about 45 patients. The company anticipates data to be accessible in 2016. The study will be led by Adi Diab, MD, Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, MD Anderson. Additional trials as part of the broader, clinical research alliance are presently in the planning stages.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, counting toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology.
At the end of Thursday’s trade, Shares of NeoPhotonics Corp (NYSE:NPTN), gained 7.14% to $ 9.91.
NeoPhotonics Corp, declared the closing of a follow-on offering of 5,971,034 shares of its common stock in a registered public offering at $7.25 per share. NeoPhotonics has granted the underwriters a 30-day option to purchase up to 895,655 additional shares of common stock to cover over-allotments.
Needham & Company, LLC acted as sole book-running manager for the offering. Craig-Hallum Capital Group LLC and B. Riley & Co. acted as co-managers.
NeoPhotonics Corporation designs and manufactures hybrid photonic integrated optoelectronic modules and subsystems for bandwidth-intensive, high-speed communications networks.
Finally, NextEra Energy Inc (NYSE:NEE), ended its last trade with 0.55% gain, and close at $ 99.67.
NextEra Energy, declared that HEI shareholders have approved the merger agreement with NextEra Energy, Inc. (NEE) declared Dec. 3, 2014.
“We’re extremely happy that our shareholders, many of whom are Hawaiian Electric, Maui Electric and Hawaii Electric Light customers, have shown their strong support for this historic partnership by approving the projected merger,” said Jeff Watanabe, HEI’s chairman of the board. “The approval marks another noteworthy milestone in our efforts to accelerate Hawaii’s clean energy transformation by bringing the expertise and resources of NextEra Energy to our state to achieve even higher levels of renewables and lower energy costs for our customers.”
NextEra Energy, Inc., through its auxiliaries, generates, transmits, and distributes electric energy in the United States and Canada. The company generates electricity from gas, oil, solar, coal, petroleum coke, nuclear, and wind sources. As of December 31, 2014, it served about 9 million people through about 4.7 million customer accounts in the east and lower west coasts of Florida.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
